Placebo-controlled results of RewinD-LB clinical trial published in Alzheimer’s Research & Therapy provides further evidence of the potential of neflamapimod to slow clinical disease progression in DLB Translational research findings published in Cells demonstrate that neflamapimod blocks a key mechanism by which neuroinflammation damages neurons in DLB and other neurodegenerative diseases BOSTON , Oct. 29, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) ( CervoMed or the Company) today announced that results from placebo-controlled phase of the Phase 2b RewinD-LB clinical trial of neflamapimod in dementia with Lewy bodies (DLB) have been published in Alzheimer's Research & Therapy . The paper follows another recent publication in Cells reporting preclinical and clinical data that demonstrated neflamapimod’s inhibition of IL-1β signaling and modulation of neuroinflammatory processes implicated in cognitive decline in DLB and other neurodegenerative diseases. “The placebo-controlled RewinD-LB data set, together with the Phase 2a results, provides encouraging evidence that neflamapimod may be an effective treatment for DLB and that further clinical evaluation is warranted,” said John-Paul Taylor , MBBS, MRCPsych, PhD, Professor of Translational Dementia Research at Newcastle University , chief investigator of the RewinD-LB trial in the United Kingdom and first author of the Alzheimer’s Research & Therapy publication . “ Taken together, these two important publications suggest that neflamapimod may be able to act on the underlying disease processes in DLB and make a meaningful difference for patients and caregivers who currently have limited therapeutic options .” “These publications demonstrate beneficial effects of neflamapimod on clinical endpoints and biomarkers of the underlying disease process that follow a consistent plasma drug-response relationship, with activity most evident at trough plasma concentrations of approximately 4 ng/mL or higher,” said Dr. John Alam , Founder and CEO of CervoMed . “We believe the alignment of clinical, biomarker, and imaging findings supports further development, particularly in patients without Alzheimer’s disease co-pathology, and reinforces the rationale for a 100 mg twice-daily dose using the new tablet formulation. This regimen is projected to achieve target trough concentrations in more than 90% of participants, providing more consistent drug exposure within the range associated with clinical activity in our prior clinical trials without substantially increasing peak concentrations or overall exposure.” Alzheimer's Research & Therapy Publication Title: A Phase 2b Randomized Clinical Trial of the Oral p38α Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB)The publication reports results from the placebo-controlled phase of CervoMed’s Phase 2b RewinD-LB clinical trial, a 159-patient trial of neflamapimod 40 mg, three times daily. Key findings from the study include: Neflamapimod did not confirm the results of CervoMed’s Phase 2a AscenD-LB clinical trial with respect to the primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), in the full intention-to-treat population. In an MRI substudy, neflamapimod demonstrated a statistically significant increase in right basal forebrain volume compared with placebo, consistent with an effect on the underlying disease process. On CDR-SB, neflamapimod showed greater benefit versus placebo in patients without Alzheimer’s disease (AD) co-pathology, as identified by low blood pTau181 levels. Placebo-adjusted differences were −0.51 points (95% CI: −1.16 to 0.13) at pTau181 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.